Search Results
25 Results Found for “hepatocellular carcinoma”
At EASL 2026, Lung-Yi Loey Mak discusses evolving hepatitis B management in young patients, including early treatment strategies, perinatal prevention, global practice variations and emerging approaches to cancer risk prediction.
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased over the past three decades and is estimated to be 30% as of 2022.1Â As an indication of disease burden, MASLD-related liver transplantation has already surpassed many other aetiologies as ...
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
New research is shedding light on the evolving landscape of liver transplants (LT) for non-cancer conditions in the United States. Dr Abdellatif Ismail (University of Maryland Medical Center, Midtown Campus, Baltimore, MD, USA) focuses on how underlying liver diseases – and ...
In this recent video interview hosted by Sarah Manes, Liver Cancers Program Director at the Global Liver Institute (GLI), medical experts from the USA, Cameroon and Mexico came together to address the significant health disparities in rural communities. The discussion ...
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1Â It has two forms: the first is a membrane-bound form, which ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver diseases, including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1 NAFLD is associated with metabolic disorders, including obesity, hypertension, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypothyroidism and metabolic syndrome.2 ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which includes a broad range of articles selected for their evaluation of current practices and research that directly affect endocrinologists as well as being of interest to the wider biomedical community. ...
Non-alcoholic fatty liver disease (NAFLD), which impacts an estimated 25% of the world’s adult population,1–3 is the principal cause of chronic liver disease globally. NAFLD as a whole represents a pathological spectrum of liver injury, spanning from simple steatosis to ...
Obesity – a chronic, relapsing, progressive disease that is defined by a body mass index (BMI) of ≥27.5 kg/m2 in Asian populations and ≥30.0 kg/m2 in all other populations – is an epidemic that has spread across the world.1 Recent data from ...
Non-alcoholic fatty liver disease (NAFLD) consists of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is unclear which specific patients progress from NAFL to NASH and, ultimately, to cirrhosis. However, there is general consensus that, for those patients who ...
Immune checkpoints are small molecules that are present on the cell surface of T lymphocytes to regulate the immune response. While some of these molecules enhance the stimulatory signals, others boost the inhibitory signals to blunt the activity of T ...
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease globally; it is histologically classified into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1Â NAFL is characterized by the presence of >5% of hepatic steatosis without ...
The prevalence of obesity is rapidly increasing across the world. In India, about 12.6% women and 9.3% men are obese, amounting to more than a 100 million population.1Â Obesity, which was earlier considered to be a growing problem only in metropolitan cities, is ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
